Cargando…
OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
BACKGROUND: Melanoma in people of Asian descent presents primarily in non-sun-exposed areas, such as acral and mucosal melanoma. Compared with the predominant sun-exposed area melanomas in Caucasians, acral and mucosal melanomas do not respond as well to immunotherapy and are associated with a worse...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984036/ https://www.ncbi.nlm.nih.gov/pubmed/35383116 http://dx.doi.org/10.1136/jitc-2021-004307 |
_version_ | 1784682092639027200 |
---|---|
author | Cui, ChuanLiang Wang, Xuan Lian, Bin Ji, Qing Zhou, Li Chi, Zhihong Si, Lu Sheng, Xinan Kong, Yan Yu, Jiayi Li, Siming Mao, Lili Tang, Bixia Dai, Jie Yan, Xieqiao Bai, Xue Andtbacka, Robert Guo, Jun |
author_facet | Cui, ChuanLiang Wang, Xuan Lian, Bin Ji, Qing Zhou, Li Chi, Zhihong Si, Lu Sheng, Xinan Kong, Yan Yu, Jiayi Li, Siming Mao, Lili Tang, Bixia Dai, Jie Yan, Xieqiao Bai, Xue Andtbacka, Robert Guo, Jun |
author_sort | Cui, ChuanLiang |
collection | PubMed |
description | BACKGROUND: Melanoma in people of Asian descent presents primarily in non-sun-exposed areas, such as acral and mucosal melanoma. Compared with the predominant sun-exposed area melanomas in Caucasians, acral and mucosal melanomas do not respond as well to immunotherapy and are associated with a worse prognosis. Hence, there is an urgent need for improved treatment for melanoma in Asians. This phase Ib trial evaluated the safety and efficacy of the modified herpes simplex virus-1 oncolytic virus OrienX010 in Chinese patients with unresectable stage IIIC–IV melanoma. METHODS: Patients were treated in two different cohorts. In cohort 08 (n=12), patients received up to 5 mL of 8×10(7) pfu/mL OrienX010 intratumoral injections every 2 weeks until disease progression and responses were evaluated every 6 weeks. In cohort 09 (n=14), patients received up to 10 mL of 8×10(7) pfu/mL OrienX010 intratumoral injections and responses were evaluated every 8 weeks. RESULTS: Between June 2014 and May 2017, 26 patients were enrolled, including 18 (69.2%) patients with acral melanoma. Fever and injection site reaction were the most frequent adverse events. Only one patient experienced a grade ≥3 adverse event and no dose-limiting toxicities were observed. The objective response rate was 19.2% and the disease control rate was 53.8%. The median duration of response was 6.0 months. Antitumor effects were observed in 54.6% of injected lesions and 48.8% of non-injected lesions, including one (16.7%) of six evaluable distant lung metastases. The median progression-free survival was 2.9 months and overall survival was 19.2 months. Compared with patients treated in cohort 08, patients treated in cohort 09 had an improved objective response rate (28.6% vs 8.3%) and a median progression-free survival of 3.0 months vs 2.8 months. CONCLUSIONS: OrienX010 oncolytic virotherapy has a tolerable safety profile with antitumor effects in both injected and non-injected metastases and warrants further evaluation in patients with melanoma. Based on these results, the higher cohort 09 dose (up to 10 mL of 8×10(7) pfu/mL every 2 weeks) was selected as the recommended phase II dose for ongoing trials. TRIAL REGISTRATION NUMBER: CTR20140631 (cohort 08), CTR20150881 (cohort 09). |
format | Online Article Text |
id | pubmed-8984036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-89840362022-04-22 OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study Cui, ChuanLiang Wang, Xuan Lian, Bin Ji, Qing Zhou, Li Chi, Zhihong Si, Lu Sheng, Xinan Kong, Yan Yu, Jiayi Li, Siming Mao, Lili Tang, Bixia Dai, Jie Yan, Xieqiao Bai, Xue Andtbacka, Robert Guo, Jun J Immunother Cancer Oncolytic and Local Immunotherapy BACKGROUND: Melanoma in people of Asian descent presents primarily in non-sun-exposed areas, such as acral and mucosal melanoma. Compared with the predominant sun-exposed area melanomas in Caucasians, acral and mucosal melanomas do not respond as well to immunotherapy and are associated with a worse prognosis. Hence, there is an urgent need for improved treatment for melanoma in Asians. This phase Ib trial evaluated the safety and efficacy of the modified herpes simplex virus-1 oncolytic virus OrienX010 in Chinese patients with unresectable stage IIIC–IV melanoma. METHODS: Patients were treated in two different cohorts. In cohort 08 (n=12), patients received up to 5 mL of 8×10(7) pfu/mL OrienX010 intratumoral injections every 2 weeks until disease progression and responses were evaluated every 6 weeks. In cohort 09 (n=14), patients received up to 10 mL of 8×10(7) pfu/mL OrienX010 intratumoral injections and responses were evaluated every 8 weeks. RESULTS: Between June 2014 and May 2017, 26 patients were enrolled, including 18 (69.2%) patients with acral melanoma. Fever and injection site reaction were the most frequent adverse events. Only one patient experienced a grade ≥3 adverse event and no dose-limiting toxicities were observed. The objective response rate was 19.2% and the disease control rate was 53.8%. The median duration of response was 6.0 months. Antitumor effects were observed in 54.6% of injected lesions and 48.8% of non-injected lesions, including one (16.7%) of six evaluable distant lung metastases. The median progression-free survival was 2.9 months and overall survival was 19.2 months. Compared with patients treated in cohort 08, patients treated in cohort 09 had an improved objective response rate (28.6% vs 8.3%) and a median progression-free survival of 3.0 months vs 2.8 months. CONCLUSIONS: OrienX010 oncolytic virotherapy has a tolerable safety profile with antitumor effects in both injected and non-injected metastases and warrants further evaluation in patients with melanoma. Based on these results, the higher cohort 09 dose (up to 10 mL of 8×10(7) pfu/mL every 2 weeks) was selected as the recommended phase II dose for ongoing trials. TRIAL REGISTRATION NUMBER: CTR20140631 (cohort 08), CTR20150881 (cohort 09). BMJ Publishing Group 2022-04-05 /pmc/articles/PMC8984036/ /pubmed/35383116 http://dx.doi.org/10.1136/jitc-2021-004307 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Oncolytic and Local Immunotherapy Cui, ChuanLiang Wang, Xuan Lian, Bin Ji, Qing Zhou, Li Chi, Zhihong Si, Lu Sheng, Xinan Kong, Yan Yu, Jiayi Li, Siming Mao, Lili Tang, Bixia Dai, Jie Yan, Xieqiao Bai, Xue Andtbacka, Robert Guo, Jun OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study |
title | OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study |
title_full | OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study |
title_fullStr | OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study |
title_full_unstemmed | OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study |
title_short | OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study |
title_sort | orienx010, an oncolytic virus, in patients with unresectable stage iiic–iv melanoma: a phase ib study |
topic | Oncolytic and Local Immunotherapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984036/ https://www.ncbi.nlm.nih.gov/pubmed/35383116 http://dx.doi.org/10.1136/jitc-2021-004307 |
work_keys_str_mv | AT cuichuanliang orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT wangxuan orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT lianbin orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT jiqing orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT zhouli orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT chizhihong orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT silu orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT shengxinan orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT kongyan orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT yujiayi orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT lisiming orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT maolili orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT tangbixia orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT daijie orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT yanxieqiao orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT baixue orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT andtbackarobert orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy AT guojun orienx010anoncolyticvirusinpatientswithunresectablestageiiicivmelanomaaphaseibstudy |